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Introduction
Polycystic Ovary Syndrome (PCOS) is a disorder of the 
reproductive system and is seen in 5 to 10% of the wom-
en in reproductive ages (1). Its main features are hyper-
androgenism both clinical or biochemical and/or chronic 
oligo-anovulation and/or ultrasonographic appearance of 
the polycystic ovaries (2). 
There are many studies showing the relationship between 
PCOS and Cardiovascular Diseases (CVD). Insulin resis-
tance, obesity, hypertension, hyperlipidemia, hypercoagu-
lability, and endothelial dysfunction can be seen frequent-
ly in PCOS patients along with increased cardiovascular 
risks (3). Previously published data show that coronary 
atherosclerosis and increased carotid intima-media thick-
ness can be observed in PCOS (4).  
The aim of our study was to determine the effects of met-
abolic factors on myocardial functions in PCOS patients, 
by measuring the strain (S) and strain rate (SR) as means 
of quantification of myocardial functions, which were first 
described by Heimdal et al. to define the global and re-
gional myocardial dysfunction (5), and to identify the pos-
sible subclinical impairment of left ventricular myocardial 
function because of the metabolic components of PCOS.
Materials and Methods
Study population
This study was carried out with 26 PCOS patients referred 
to the Obstetrics and Gynecology Clinic of Baskent Uni-
versity Hospital between December 2008 and September 
2009 and 23 healthy female volunteers as control group. 
The PCOS patients were diagnosed in accordance with 
2003 Rotterdam criteria (2). There were neither menstrual 
cycle abnormalities nor hyperandrogenism in the control 
group both clinically and biochemically. Clinical symp-
toms of hyperandrogenism were acne and/or hirsutism. A 
score higher than 7 based on the modified Ferriman-Gall-
wey Scale was noted as hirsutism. Any disease other than 
PCOS including hypertension, diabetes, thyroid function 
abnormalities, Cushing syndrome, asthma, and other au-
to-immune diseases, and all medical conditions which 
caused regular drug use were exclusion criteria for our 
study. All participants signed the informed consent before 
enrolling in our study. 
A physical examination with a detailed anamnesis includ-
ing body weight and height were performed in all partic-
ipants. Body Mass Index (BMI) was determined as body 
weight (kilograms) divided by height (meters) squared. 
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Laboratory measurements
The participants having a regular menstrual cycle gave 
their blood samples between third and seventh day of 
their cycle. The participants with irregular menstrual cy-
cle gave their blood samples irrespective of their cycle day. 
The blood samples of the participants were taken between 
08:00-12:00 am, after 12 hours of fasting.
High sensitive C-reactive protein (hsCRP) was measured 
with a turbidimetric method by using an Abbott® Archi-
tect C8000 device. Total cholesterol, triglyceride, Low 
Density Lipoprotein (LDL), and High Density Lipoprotein 
(HDL) were measured with an enzymatic colorimetric 
method by using a Roche/Hitachi Modular PP (Roche Di-
agnostics GmbH, Mannheim, Germany). Serum glucose 
levels were detected with hexokinase method by using a 
Roche/Hitachi Modular PP (Roche Diagnostics GmbH, 
Mannheim, Germany). Hemogram tests were performed 
after the anticoagulation with K3EDTA by using an Ab-
bott Cell-Dyne® 3700 System (Abbott Diagnostics, Santa 
Clara, CA, USA).
Estradiol (e2), Follicle Stimulating Hormone (FSH), Lu-
teinizing Hormone (LH), prolactin, and insulin levels were 
measured with an immunometric method by using an 
Immulite® 2000 (Siemens Medical Solutions Diagnostics, 
Los Angeles, CA). Free testosterone tests were performed 
with Radioimmunoassay method (RIA) (Diagnostics Sys-
tems Laboratories, Webster, TX). 17-OH-progesterone 
tests were performed with RIA by using BioSource Europe 
S.A., Nivelles, Belgium. 
The Homeostasis Model Assessment Insulin Resistance 
index (HOMA-IR) was determined by using the follow-
ing formula: fasting insulin (mU/L) × fasting glucose (mg/
dL)/22.5 (6). HOMA-IR value more than 2.5 was indica-
tive of insulin resistance (7).
 
Echocardiographic examination
Transthoracic echocardiographic examinations were con-
ducted with a commercially available cardiac ultrasound 
system (Acuson Sequoia C256, Acuson Siemens, Moun-
tain View, CA, USA) equipped with a broadband 3.5 MHz 
transducer with second harmonic capabilities. All patients 
were examined with standard 2D and Doppler echocardi-
ography conforming to the American Society of Echocar-
diography (ASE) and European Association of Echocardi-
ography recommendations (8). In addition, longitudinal 
myocardial systolic and diastolic velocities at the mitral 
annular level from the lateral and septal sites were mea-
sured by using pulsed wave tissue Doppler in the apical 
4-chamber view. 
Left ventricular longitudinal myocardial systolic and dia-
stolic velocities, systolic SR and systolic S were measured 
from the apical 2- and 4-chamber views and averaged by 
using the Syngo WST 3.0 software. A narrow angle with 
an optimal image depth was used to obtain a high frame 
rate (>100 frames/s) and avoid angulations. All echocar-
diographic measurements were performed by the same 
echocardiographer blinded to the clinical information of 
the patients.
Statistical analyses
All analyses were conducted by using the SPSS software 
(Statistical Package for the Social Sciences, version 15.0, 
SSPS Inc., Chicago, IL, USA). Continuous variables were 
expressed as mean ± Standard Deviation (SD) or median 
(interquartile range) and categorical variables as percent-
ages. The normality of distribution was tested by the Sha-
piro-Wilk test. Variables with a normal distribution were 
compared by a Student-T test or univariate analysis of 
variance (ANOVA). Variables that showed a non-homo-
geneous distribution were compared by the Mann Whit-
ney U-test. The comparisons of the categorical variables 
were performed with the chi-square test. Correlations 
were evaluated by the Spearman’s correlation test. A ‘P’ 
value lower than 0.05 was noted as statistically significant.
Results
Age intervals for PCOS and control group were similar 
(Table 1). LH, LH/FSH ratio, BMI, fasting serum glu-
cose, HOMA-IR and insulin were higher in PCOS group 
(P<0.05) (Table 1). FSH, HDL were lower in PCOS group 
(P<0.05) (Table 1). Eight PCOS patients (31%) had insu-
lin resistance. There were 10 (39%) people in PCOS group 
and 1 (4%) people in the control group in whom BMI val-
ues were greater than 30. The number of people having 
a BMI between 25 and 29.9 was 7 (27%) in PCOS group 
and 5 (22%) in control group. The other participants’ 
BMI values were in normal range. Also, all participants’ 
electrocardiograms were in normal range. Waist circum-
ference measurement and the ratio of waist circumfer-
ence to thigh circumference were higher in PCOS group 
(P<0.05) (Table 1). 
No differences were detected between the two groups’ 
conventional echocardiographic measurements (Table 2). 
Myocardial velocities, strain and strain rate measurements 
(Table 3) were also similar between the groups both for 
regional and global indices. No differences were found be-
tween the strain measurements of participants whose BMI 
was greater or less than 25. Similarly, comparing the over-
weight PCOS patients’ (BMI>25) strain measurements 
with that of normal weight PCOS patients’ (BMI<25) 
measurements, we found no differences.
Discussion
PCOS is thought to be an endocrine disorder which in-
creases the cardiovascular risks (9). It was shown that 
metabolic complications associated with PCOS such as 
hyperinsulinemia, insulin resistance and dyslipidemia are 
major risk factors for atherosclerosis (9). In our study, we 
found fasting glucose (10), insulin, HOMA-IR and BMI 
to be higher and HDL to be lower in PCOS group (11,12). 
In PCOS group, obesity and irregularity of sex hormones 
were more evident as expected. 
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Our echocardiographic parameters were similar for both 
groups. The first parameter of our echocardiographic ex-
amination was left ventricular ejection fraction and our 
results were similar for the PCOS patients and the control 
group, consistent with results of Tekin’s study (13).  Howev-
er, Orio et al. found lower left ventricular ejection fraction 
in overweight PCOS patients than the overweight con-
trol group (12). Although 65% of the PCOS patients and 
26% of the control group in our study were overweight or 
obese, we could not find similar results to Orio’s study for 
left ventricular ejection fraction measurements. Previous 
studies suggested that some factors such as obesity, insulin 
resistance and age could affect the myocardial strain mea-
surements. Obesity can cause a subclinical impairment in 
myocardial functions alone (14,15). Insulin resistant peo-
ple can show subclinic deterioration in myocardial func-
tions (16). In our study, only 31% of PCOS patients had 
insulin resistance and this low percentage of insulin resis-
tant patients can possibly explain the similarity between 
the PCOS and control groups strain measurements. 
Our mitral inflow and mitral velocity results used for 
measuring left ventricular diastolic functions revealed no 
differences between both groups as in Tekin’s study (13), 
yet in Erdogan et al. study mitral velocities were lower in 
PCOS patients (17). 
In another study, myocardial peak systolic strain, peak 
Table 1. Baseline characteristics and laboratory results of the study population
Clinical characteristics PCOS (N=26) Control (N=23) P
Age (years) 25.9 ± 5.8 25.7 ± 2.8 NSⁿ
Females 100 (%) 100 (%) NS#
Body mass index (kg/m²) 28 ± 5.1 22 ± 2.9 0.00ⁿ 
Waist circumference (cm) 84 ± 12 72 ± 8.6 0.00ⁿ
Waist to hip ratio 0.76 ±0.06 0.72 ± 0.05 0.009ⁿ
Hirsutismus 76.9 (%) 13.0 (%) 0.00#
Laboratory results
Fasting serum glucose (mg/dL) 90 ± 8.0 79 ± 7.0 0.00ⁿ
Total cholesterol level (mg/dL) 174 ± 37 167± 30 NSⁿ
HDL (mg/dL) 46± 9 58 ± 16 0.03ⁿ
LDL  (mg/dl) 98 ± 32 86 ± 25 NSⁿ
Triglycerides (mg/dL) 96 ± 46 78 ± 40 NSⁿ
High sensitive C-reactive protein (mg/L) 2.9 ± 2.8 1.2 ± 1.0 NSⁿ
FSH  (mIU/ml) 4.9 (0.7-7) 6.5 (0.8-10) 0.007*
LH  (mIU/ml) 6.3 (0.8-21) 4.3 (0.7-12) 0.01*
LH/FSH 1.3 (0.3-5) 0.7 (0.09-3) 0.00*
Prolactin (ng/ml) 12 (5-65) 20 (5-44) NS*
Free testosterone (pg/ml) 1.1 (0.2-3.1) 0.7 (0.3-3.1) NS*
DHEA-S (µg/dl) 240 (73-522) 270 (114-723) NS*
Estradiol (pg/ml) 44 (20-158) 42 (20-134) NS*
17-OH-progesteron (µgr/ml) 1.0 (0.4-6.8) 1.2 (0.6-2.4) NS*
Insulin (µIU/ml) 5.8 (2.8-50) 4.7 (2-10) 0.01*
HOMA-IR value 2.5 ± 2.6 0.9 ± 0.4 0.006ⁿ
Hemoglobin (g/dL) 13 ± 1 13 ± 1 NSⁿ
Leucocytes (1000/µL) 6.303 ± 2 6.103 ± 1 NSⁿ
Thrombocytes (1000/µl) 290 ± 73 274 ± 67 NSⁿ
The median (interquartile range), or frequency counts (percentages), as appropriate. DHEA-S= Dehydroepiandrosterone sulfate; FSH= 
Follicular Stimulating Hormone; HDL= High Density Lipoprotein; LDL= Low Density Lipoprotein; LH= Luteinizing Hormone; NS= no 
significant difference; PCOS= Polycystic Ovary Syndrome; 
ⁿt-test; *Mann–Whitney U-test; #χ2-test.
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early diastolic strain, and peak early diastolic velocity 
measurements were found to be lower in obese (BMI>30), 
insulin resistant PCOS patients (18).  However, we could 
not find any difference in our PCOS group. This can be 
explained by the small number of insulin resistant PCOS 
patients [8 (31%)] in our study.
In a study of overweight PCOS patients, longitudinal strain 
measurements were lower than the control group (17). The 
same study found higher HOMA-IR and insulin levels in 
PCOS group than the control group, yet the percentage 
of insulin resistant participants was not mentioned (17). 
Although the PCOS patients’ insulin, HOMA-IR and BMI 
values were higher than the control group in our study, we 
did not find any impairment of the left ventricular func-
tion in both groups. This could be explained by the young 
age of the participants in our study resulting in shorter 
durations as PCOS. Cardiological examination should be 
advised to these patients in the future. 
Conclusion 
In conclusion, according to our study PCOS patients with 
no clinical cardiovascular symptoms have no impair-
ment in myocardial functions. Larger controlled studies 
are needed for further understanding and validating our 
results.
Ethical issues
Approval of the local ethics committee from “Baskent 
University Clinical Research Ethics Committee” was tak-
en before the study was begun.
Table 2. Echocardiographic data of the patients with PCOS and controls
Echocardiographic data PCOS (N=26) Control (N=23) P
2 Dimensional measurements
IVS (cm) 0.8 (0.5-1.1) 0.7 (0.5-1.0) NS*
PW (cm) 0.8 (0.5-1.1) 0.7 (0.5-1.0) NS*
LVDD (cm) 3.9 ± 0.2 3.7 ± 0.2 NSⁿ
LVSD (cm) 2.4 ± 0.2 2.4 ± 0.2 NSⁿ
EF (%) 57 (51-70) 57 (51-66) NS*
EDV (ml) 83 (56-124) 79 (57-119) NS*
ESV (ml) 36 ± 9 34 ± 8 NSⁿ
SV (ml) 45 ± 12 43 ± 10 NSⁿ
LVMI (g/m²) 55 ± 14 48 ± 9 NSⁿ
Tissue Doppler measurements
Mitral lateral S velocity  (cm/s) 11 ± 2 11 ± 3 NSⁿ
Mitral septal S velocity (cm/s) 8.3 ± 1.8 8.7 ± 2.8 NSⁿ
Mitral lateral E’ velocity  (cm/s) 17 ± 3 17 ± 4 NSⁿ
Mitral septal E’ velocity (cm/s) 13 ± 2 14 ± 4 NSⁿ
Mitral E-wave (cm/s) 77 ±25 81 ±12 NSⁿ
Mitral A-wave (cm/s) 56 ±9 61 ±10 NSⁿ
E/A  1.4 ± 0.5 1.3 ± 0.2 NSⁿ
E/E’ lateral 4.4 ± 1.5 5.0 ± 1.3 NSⁿ
E/E’ septal 6.1 ± 2.1 5.9 ± 1.8 NSⁿ
Measurements related to doppler assessment
Baseline heart rate (beats/min) 69 ± 11 71 ± 18 NSⁿ
Baseline SBP (mmHg) 114 ± 9 114 ± 8 NSⁿ
Baseline DBP (mmHg) 74 ± 7 74 ± 7 NSⁿ
A, late mitral inflow velocity; DBP, Diastolic Blood Pressure; E, early mitral inflow velocity; E’, early mitral annular velocity; EDV, End 
Diastolic Volume; EF, Ejection Fraction; ESV, End Systolic Volume; IVS, Interventricular Septum; LVDD, Left Ventricular Diastolic Diameter; 
LVMI, Left Ventricular Mass Index; LVSD, Left Ventricular Systolic Diameter; PCOS, Polycystic Ovary Syndrome; PW, Posterior Wall; S, 
Systolic; SBP, Systolic Blood Pressure;  SV, Stroke Volume.
ⁿ t-test;  *Mann–Whitney U-test. 
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Table 3. Regional quantitative myocardial functional data of the patients with PCOS and controls
Myocardial functional data PCOS (N=26) Control (N=23) P
Systolic Strain measurements
Strain lateral basal (%) 21.3 ± 8.6 19.6 ± 5.6 NSⁿ
Strain lateral mid (%) 17.9 ± 5.6 15.6 ± 5.8 NSⁿ
Strain lateral apical (%) 10.7 ± 4.9 12.1 ± 7.3 NSⁿ
Strain septum basal (%) 17.2 ± 6.7 16.3 ± 9.3 NSⁿ
Strain septum mid (%) 17.9 ± 5.2 17.4 ± 5.2 NSⁿ
Strain septum apical (%) 13.9 ± 6.8 15.6 ± 6.2 NSⁿ
Strain anterior basal (%) 21.8 ± 6.8 20.8 ± 8.4 NSⁿ
Strain anterior mid (%) 15.1 ± 6.3 15.6 ± 5.1 NSⁿ
Strain anterior apical (%) 10 ± 4.7 12 ± 6.0 NSⁿ
Strain inferior basal (%) 17.6 ± 7.8 18.2 ± 7.5 NSⁿ
Strain inferior mid (%) 16.7 ± 6.3 18.4 ± 5.6 NSⁿ
Strain inferior apical (%) 16.6 ± 7.0 18.7 ± 6.1 NSⁿ
Mean systolic strain
Apical 4 chamber 16.7 ± 3.2 16.1 ± 3.9 NSⁿ
Two chamber 16.1 ± 3.8 17.4 ± 4.0 NSⁿ
Systolic Strain Rate, 1/s
Strain rate lateral-basal, 1/s 1.2 ± 0.5 1.1 ± 0.3 NSⁿ
Strain rate lateral-mid, 1/s 1.0 ± 0.3 0.9 ± 0.3 NSⁿ
Strain rate lateral-apical, 1/s 0.6 ± 0.3 0.8 ± 0.4 NSⁿ
Strain rate septum-basal, 1/s 1.0 ± 0.4 1.0 ± 0.7 NSⁿ
Strain rate septum-mid, 1/s 1.0 ± 0.2 0.9 ± 0.2 NSⁿ
Strain rate septum-apical, 1/s 0.8 ± 0.3 0.9 ± 0.2 NSⁿ
Strain rate anterior-basal, 1/s 1.2 ± 0.4 1.3 ± 0.6 NSⁿ
Strain rate anterior-mid, 1/s 0.8 ± 0.3 0.9 ± 0.3 NSⁿ
Strain rate anterior-apical, 1/s 0.6 ± 0.2 0.7 ± 0.3 NSⁿ
Strain rate inferior-basal, 1/s 1.0 ± 0.6 1.1 ± 0.5 NSⁿ
Strain rate inferior-mid, 1/s 0.9 ± 0.3 1.1 ± 0.6 NSⁿ
Strain rate inferior-apical, 1/s 0.9 ± 0.4 1.2 ± 0.5 NSⁿ
Mean systolic strain rate
Apical 4 chamber 0.9 ± 0.2 0.9 ± 0.2 NSⁿ
Two chamber 0.9 ± 0.2 1.1 ± 0.3 NSⁿ
Systolic Velocity (cm/sn)
Velocity lateral-basal, cm/sn 4.2 ± 1.5 4.0 ± 1.1 NSⁿ
Velocity lateral-mid, cm/sn 2.3 ± 1.4 2.3 ± 1.2 NSⁿ
Velocity lateral-apical, cm/sn 0.7 ± 0.7 0.8 ± 0.6 NSⁿ
Velocity septum-basal, cm/sn 4.4 ± 1.1 4.4 ± 0.7 NSⁿ
Velocity septum-mid, cm/sn 2.4 ± 0.6 2.8 ± 1.0 NSⁿ
Velocity septum-apical, cm/sn 1.0 ± 0.8 0.9 ± 0.7 NSⁿ
Velocity anterior-basal, cm/sn 3.8 ± 1.5 4.1 ± 1.3 NSⁿ
Velocity anterior-mid, cm/sn 1.7 ± 0.7 2.1 ± 1.2 NSⁿ
Velocity anterior-apical, cm/sn 0.4 ± 0.3 0.6 ± 0.5 NSⁿ
Velocity inferior-basal, cm/sn 4.5 ± 1.0 4.7 ± 1.3 NSⁿ
Velocity inferior-mid, cm/sn 2.8 ± 0.8 3.0 ± 0.7 NSⁿ
Velocity inferior-apical, cm/sn 0.8 ± 0.4 1.0 ± 0.4 NSⁿ
Mean Systolic Velocity (cm/sn)
Apical 4 chamber 2.4 ± 0.6 2.6 ± 0.5 NSⁿ
Two chamber 2.4 ± 0.6 2.6 ± 0.6 NSⁿ
ⁿ t-test. 
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